Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
579 hedge funds and large institutions have $35.6B invested in Alexion Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 101 funds opening new positions, 215 increasing their positions, 198 reducing their positions, and 36 closing their positions.
181% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 36
38% more funds holding in top 10
Funds holding in top 10: 13 → 18 (+5)
12% more capital invested
Capital invested by funds: $31.9B → $35.6B (+$3.77B)
11% more funds holding
Funds holding: 522 → 579 (+57)
9% more repeat investments, than reductions
Existing positions increased: 215 | Existing positions reduced: 198
7% less call options, than puts
Call options by funds: $156M | Put options by funds: $168M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$379M |
| 2 |
TG
TCW Group
Los Angeles,
California
|
+$115M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
+$91.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$86.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$82.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$480M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$335M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$175M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$87.3M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$63.6M |
ALXN Hedge Fund Activity: Q4 2014 in Review
579 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q4 2014, worth a combined $35.6B — up 12% from $31.9B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new ALXN positions and 36 closed out — a net gain of 65 holders — while 215 added to existing stakes and 198 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $379M. The largest seller was Jennison Associates, cutting an estimated $480M.
- 579 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q4 2014, up from 522 in Q3 2014.
- Funds reported $35.6B of Alexion Pharmaceuticals stock for Q4 2014, up 12% quarter-over-quarter.
- 101 funds opened new Alexion Pharmaceuticals positions in Q4 2014 and 36 closed out, a net change of +65 holders.
- The largest Alexion Pharmaceuticals buyer in Q4 2014 was Fidelity Investments, an estimated $379M added.
- The largest Alexion Pharmaceuticals seller in Q4 2014 was Jennison Associates, an estimated $480M sold.
Based on aggregated 13F filings for Q4 2014.